Introduction
Sweet syndrome was first reported in 1964 in the British Journal of Dermatology by Dr. Robert Douglas Sweet, who described eight women with skin eruptions, fever, and neutrophilic leukocytosis [1] . Sweet syndrome has since been associated with a range of disorders and is currently categorized into three subtypes based on etiology, namely as classical Sweet syndrome, malignancy-associated Sweet syndrome, and drug-induced Sweet syndrome. The first-line treatment for this condition is high-dose systemic corticosteroid therapy. Commonly used alternative medications include colchicine, dapsone, and potassium iodide [2] . There is a dearth of literature on cases of Sweet syndrome refractory to standard treatment, and even fewer reports of Sweet syndrome treated with anakinra [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Case Presentation
A 19-year-old female with a past medical history significant for long-standing Sweet syndrome requiring multiple emergency department visits presented to the emergency department with generalized muscle and joint pain and a diffuse outbreak of papules and vesicles. Her condition had been refractory to corticosteroids, colchicine, dapsone, adalimumab, abatacept, infliximab, etanercept, azathioprine, leflunomide, lenalidomide, and methotrexate, and was being managed with tocilizumab. The patient's condition was consistent with an acute exacerbation of Sweet syndrome and she was treated and discharged on a 40 mg prednisone taper.
Two days after this visit, the patient returned to the emergency department with worsening muscle and joint pain and a new eruption of diffuse skin lesions. Vital signs revealed a temperature of 36.7°C, pulse of 104 beats per minute, blood pressure of 139/90 mmHg, respiratory rate of 18, and oxygen saturation of 99% on room air. Physical examination revealed tender, erythematous, and ulcerating papules and pustules scattered over the trunk, bilateral upper and lower extremities, and face. Laboratory workup was notable for a leukocyte count of 16,800 cells/μL in the setting of recent steroid use, platelet count of 411,000 platelets/μL, creactive protein of 1.15 mg/L, and erythrocyte sedimentation rate of 37 mm/h.
The patient was admitted and started on 250 mg of methylprednisolone twice per day and colchicine 0.6 mg twice per day but continued to develop new lesions on her face, lower back, and tongue. Pain management was attempted with acetaminophen, gabapentin, tizanidine, duloxetine, and toradol, and ultimately the patient's pain was controlled with hydromorphone 4 mg taken every three hours as needed. The patient was given 100 mg of anakinra and her skin lesions began to improve. She was discharged with oral pain medications after a seven-day inpatient stay and followed up with outpatient rheumatology for continued treatment.
Discussion
Sweet syndrome is an uncommon disorder and therefore it is often missed on initial presentation. Specific diagnostic criteria have been established for each subtype of this syndrome ( Tables 1-2 ). Classical Sweet syndrome represents the majority of cases and develops most commonly in individuals between the ages of 30 and 60 in the settings of inflammatory bowel disease, pregnancy, or a few weeks after an upper respiratory or gastrointestinal infection [2] . Malignancy-associated Sweet syndrome can occur before, after, or concurrently with either a solid tumor or hematologic malignancy. This subtype tends to affect older patients, with one study estimating the average age at diagnosis of 68 years old [15] . Druginduced Sweet syndrome usually develops a few weeks after initial drug exposure and is most commonly due to granulocyte-colony stimulating factor (G-CSF). All subtypes of this syndrome have a female predominance [2] . The diagnosis of drug-induced Sweet syndrome requires all five criteria to be met [2] .
Major criteria Minor criteria
The pathogenesis of this disorder is not well understood but is theorized to be at least partially due to cytokine dysregulation. G-CSF is believed to contribute to this disorder because it increases circulating neutrophils. In support of this, one study comparing patients with active and inactive Sweet syndrome revealed elevated production of G-CSF in patients with active Sweet syndrome [16] . In another study, interleukin-1, interleukin-2, and interferon-gamma were found to be elevated in patients with active Sweet syndrome [17] . These findings are supported by the efficacy of certain immunomodulatory drugs in cases of refractory Sweet syndrome and by the fact that interleukin-1 induces endothelial cell release of G-CSF [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 18] .
Our patient's case is distinct from previous reports because she failed both standard corticosteroid and colchicine therapies, and failed trials of multiple immunomodulatory medications. Her symptoms were eventually controlled with anakinra, an interleukin-1 receptor antagonist, and this response further supports the likelihood of an interleukin-1 pathway in the pathogenesis of Sweet syndrome. It also opens the possibility that our patient's case represents an example of an interleukin-1 mediated variant of Sweet syndrome and that multiple variants of this syndrome may exist, especially because the patient's symptoms were refractory to the interleukin-6 receptor inhibitor tocilizumab. It is important that further research is conducted on Sweet syndrome in a large cohort of patients in order to determine the pathogenesis as well as investigate the possibility of multiple variants.
Conclusions
Sweet syndrome should be considered in patients presenting with an abrupt onset of a diffuse rash with possible fever and leukocytosis, especially in the settings of recent drug use, malignancy, inflammatory disorder, and recent infection. In addition, anakinra should be considered in patients whose symptoms are unresponsive to both standard treatments and immunomodulators because although the syndrome itself is not fatal, it is very painful and often requires opioid therapy for appropriate pain control.
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